2-amino-N-cyclopropyl-N-methylacetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-N-cyclopropyl-N-methylacetamide
• 化学式: C₆H₁₂N₂O
• 分子量: 128.174
• InChiKey: HKILLKIISXHLBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-6-phenyl-2-(4-trifluoromethylphenyl)pyrimidine 、 2-amino-N-cyclopropyl-N-methylacetamide 在 三乙胺 作用下， 以 氯仿 、 水 为溶剂， 生成 N-cyclopropyl-N-methyl-2-[6-phenyl-2-(4-trifluoromethyl-phenyl)-4-pyrimidinylamino]acetamide
  参考文献：
  名称：

  [5-CHLORO-6-PHENYL-2-(4-TRIFLUOROMETHYLPHENYL)-4-PYRIMIDINYLAMINO]ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATE OF THESE COMPOUNDS

  摘要：

  一种公式为（I）的A [5-氯-6-苯基-2-(4-三氟甲基苯基)-4-嘧啶基氨基]乙酰胺衍生物，其中R1是甲基基团或环丙基基团，以及包含该物质的制药组合物。该化合物表现出强大的抗类风湿活性并显示低毒性，因此，它们可用作预防或治疗免疫炎症性疾病，如类风湿病（例如类风湿性关节炎、Behcet病、强直性脊柱炎等）和自身免疫疾病（例如多发性硬化症、系统性红斑狼疮、Sjögren综合征等）的药物。

  公开号：

  US06620817B1

文献信息

• Adenosine Kinase Inhibitors. 6. Synthesis, Water Solubility, and Antinociceptive Activity of 5-Phenyl-7-(5-deoxy-β-<scp>d</scp>-ribofuranosyl)pyrrolo[2,3-<i>d</i>]pyrimidines Substituted at C4 with Glycinamides and Related Compounds
  作者：Brett C. Bookser、Bheemarao G. Ugarkar、Michael C. Matelich、Robert H. Lemus、Matthew Allan、Megumi Tsuchiya、Masami Nakane、Atsushi Nagahisa、James B. Wiesner、Mark D. Erion

  DOI：10.1021/jm050394a

  日期：2005.12.1

  4-(Phenylamino)-5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine 1 and related compounds known as "diaryltubercidin" analogues are potent inhibitors of adenosine kinase (AK) and are orally active in animal models of pain such as the rat formalin paw model (GP3269 ED50= 6.4 mg/kg). However, the utility of this compound class is limited by poor water solubility that can be attributed

  4-（苯氨基）-5-苯基-7-（5-脱氧-β-D-呋喃呋喃糖基）吡咯并[2,3-d]嘧啶1和相关化合物被称为“二芳基丁二醛”类似物，是腺苷激酶（AK）的有效抑制剂。 ），并且在疼痛动物模型（例如大鼠福尔马林爪模型（GP3269 ED50 = 6.4 mg / kg））中具有口服活性。但是，该化合物类别的实用性受到水溶性差的限制，这可归因于固态的平行C4和C5芳基环的堆叠（化合物1和GP3269的pH 7.4溶解度< 0.05微克/毫升）。为了增加水溶性，疏水性C 4-苯基氨基取代基被更亲水的甘氨酰胺取代。该修饰导致改善的水溶性，同时保持AK抑制效力。研究了类似物，其中甘氨酰胺部分的变化与碱基和糖的变化结合在一起。铅化合物4-N-（N-环丙基氨基甲酰基甲基）氨基-5-苯基-7-（5-脱氧-β-D-呋喃呋喃糖基）吡咯并[2,3-d]嘧啶（16c）（IC50 = 3 nM在pH 7.4时，水溶解度=
• 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists
  申请人：Letourneau Jeffrey

  公开号：US20080214553A1

  公开（公告）日：2008-09-04

  The present invention relates to 2-(4-oxo4H-quinazolin-3-yl)acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.

  本发明涉及公式（I）的2-（4-氧代4H-喹唑啉-3-基）乙酰胺衍生物，以及它们作为利尿激素V3拮抗剂的用途，特别是用于治疗抑郁症。
• 5-CHLORO-6-PHENYL-2-(4-TRIFLUOROMETHYLPHENYL)-4-PYRIMIDINYLAMINO]ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATE OF THESE COMPOUNDS
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：EP1236721A1

  公开（公告）日：2002-09-04

  A [5-chloro-6-phenyl-2-(4-trifluoromethylphenyl)-4-pyrimidinylamino]acetamide derivative of the formula (I): wherein R1 is a methyl group or a cyclopropyl group, and a pharmaceutical composition containing the same. Said compounds exhibit a potent anti-rheumatoid activity and show low toxicity, and hence, they are useful as an agent for prophylaxis or treatment of immuno inflammatory diseases such as rheumatoid diseases (e.g., rheumatoid arthritis, Behçet disease, ankylosing spondylitis, etc.) and autoimmune diseases (e.g., multiple sclerosis, systemic lupus erythematosus, Sjögren syndrome, etc.).

  一种式（I）的[5-氯-6-苯基-2-（4-三氟甲基苯基）-4-嘧啶基氨基]乙酰胺衍生物： 其中 R1 是甲基或环丙基，以及含有这些化合物的药物组合物。上述化合物具有强效的抗类风湿活性，且毒性低，因此可用于预防或治疗免疫炎症性疾病，如类风湿病（如类风湿性关节炎、白塞氏病、强直性脊柱炎等）和自身免疫性疾病（如多发性硬化症、系统性红斑狼疮、Sjögren 综合征等）。
• 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization
  作者：Stephen W. Wright、Virginia L. Rath、Paul E. Genereux、David L. Hageman、Carolyn B. Levy、Lester D. McClure、Scott C. McCoid、R. Kirk McPherson、Teresa M. Schelhorn、Donald E. Wilder、William J. Zavadoski、E. Michael Gibbs、Judith L. Treadway

  DOI：10.1016/j.bmcl.2004.10.048

  日期：2005.1

  The synthesis, in vitro, and in vivo biological characterization of a series of achiral 5-chloroindoloyl glycine amide inhibitors of human liver glycogen phosphorylase A are described. Improved potency over previously reported compounds in cellular and in vivo assays was observed. The allosteric binding site of these compounds was shown by X-ray crystallography to be the same as that reported previously for 5-chloroindoloyl norstatine amides.
• CANNABINOID RECEPTOR LIGANDS
  申请人：AstraZeneca AB

  公开号：EP2190838A1

  公开（公告）日：2010-06-02